- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aktionäre von Revelation Biosciences stimmen Ausgabe von Stammaktien für Optionsscheine zu | 2 | Investing.com Deutsch | ||
| Mi | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| Mo | Revelation Biosciences, Inc.: Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting | 128 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing... ► Artikel lesen | |
| 20.11. | Revelation Biosciences, Inc.: Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year | 175 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| 12.11. | REVELATION BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 06.11. | Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025 | 262 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing... ► Artikel lesen | |
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.10. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.10. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date | 168 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 15.10. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.10. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025 | 339 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 16.09. | Revelation Biosciences files to sell 13.07M shares of common stock by selling shareholders | 4 | Seeking Alpha | ||
| 11.09. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds | 327 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 10.09. | Revelation Biosciences: Wirkstoffkandidat Gemini zeigt vielversprechende Ergebnisse bei chronischer Nierenerkrankung | 2 | Investing.com Deutsch | ||
| 10.09. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data | 367 | ACCESS Newswire | - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data... ► Artikel lesen | |
| 09.09. | Revelation Biosciences, Inc.: Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data | 290 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 09.09. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 09.09. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study | 223 | ACCESS Newswire | - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data... ► Artikel lesen | |
| 08.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 09.07. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 189,97 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies | Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,110 | +1,98 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARCELLX | 68,45 | -6,16 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| AVIDITY BIOSCIENCES | 71,54 | -0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 31,160 | +4,01 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| RECURSION PHARMACEUTICALS | 4,920 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| NUVALENT | 106,86 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| POLYRIZON | 14,500 | 0,00 % | Morning Market Movers: Polyrizon, Picard Medical, Crescent Biopharma, Hyster-Yale See Big Swings | OTTAWA (dpa-AFX) - At 7:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 27,640 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| KYMERA THERAPEUTICS | 66,23 | +0,36 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,810 | +2,40 % | Don't Buy Summit Therapeutics Until This Big Thing Happen | ||
| IMMUNOVANT | 22,910 | 0,00 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,995 | +12,32 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 38,250 | +3,38 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data | ||
| JANUX THERAPEUTICS | 16,400 | 0,00 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
REVELATION BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,26 % bei einem Aktienkurs von 1,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.